NAD+ on Juno

NAD+

Also known as: Nicotinamide Adenine Dinucleotide, NAD, NAD IV, NMN (precursor), NR (precursor)

Coenzyme central to redox biology, marketed as IV / SubQ / oral and via NMN/NR precursors. Most clinical claims rest on weak or contested evidence; bioavailability is a real, unresolved question.

Reviewed 2026-05-04

What it does

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme — not a peptide — present in every cell and central to redox reactions, sirtuin and PARP signaling, and mitochondrial energy metabolism. It is included in this peptide companion library because users overwhelmingly stack NAD+ (or its precursors NMN and NR) alongside peptide regimens, and because most competitors lump NAD+ in with peptides without disclosing it isn't one. Cellular NAD+ declines with age, and that observation has driven a large supplement and IV-clinic market. The clinical evidence behind raising NAD+ is weaker than the marketing, and the bioavailability question — whether oral, IV, or subcutaneous NAD+/NMN/NR meaningfully raises tissue NAD+ in ways that translate to clinical outcomes — remains genuinely contested.

Used for

Dose

Starting: 100,000 mcg · once daily
Common: 550,000 mcg · once daily
Upper: 1,000,000 mcg · once daily
When: MorningEnergy-axis activation via NAD+ pool replenishment. Morning convention from IV-clinic protocols. Evening dosing risks disrupting sleep for sensitive users.
Site: oral (as NR or NMN precursor)

Need exact volumes? Open the peptide calculator →

⚠ Caution

Active malignancy — sirtuin and NAD+ metabolism intersect with cancer biology in complex, dose- and tumor-type-dependent ways; consult oncology before use
Pregnancy and breastfeeding (no human safety data for high-dose IV/SubQ administration)
Severe cardiac arrhythmia (rapid IV infusion has caused chest pressure, tachycardia, anxiety)
Known hypersensitivity to NAD+ or compounding excipients
Caution with chemotherapy regimens whose mechanism involves NAD+/PARP signaling — discuss with oncologist

Medications & conditions

NAD+ with chemotherapy — potential PARP/DNA-repair interactionUser is undergoing chemotherapy. NAD+ is an essential cofactor for PARP enzymes, which mediate DNA damage repair. PARP inhibitors (olaparib, niraparib, etc.) specifically deplete or block this pathway to kill cancer cells — supplemental NAD+ may attenuate their mechanism. With other DNA-damaging chemotherapy agents, the interaction is less established but mechanistically plausible. Discuss with the oncology team before using NAD+ supplementation during active cancer treatment.

Often stacked with

5-Amino-1MQ — 5-Amino-1MQ inhibits NNMT to spare the nicotinamide-NAD+ pool; direct NAD+ (or precursors) replenishes the oxidised coenzyme pool — mechanistically additive but different routes/forms require separate administration.

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Co-injection & overlap

Inject separately (do not co-mix): 5-Amino-1MQ

Reconstitution & storage

NAD+ for IV / SubQ use is supplied by compounding pharmacies as either a sterile solution (e.g., 100 mg/mL) or a lyophilized powder. Not the typical sub-mg microgram-dose peptide reconstitution math: a 100 mg SubQ dose at 100 mg/mL = 1 mL = 100 units on a U-100 syringe (a full syringe). Many clinics and users prefer divided dosing or smaller volumes due to injection discomfort. NMN and NR are oral capsules / powders — no reconstitution.

Storage. Compounded sterile solutions: refrigerate 2–8 °C, follow vendor expiration. Lyophilized: refrigerate; reconstituted within 30 days typical. Oral NR / NMN: room temperature, dry, protect from light.

Open the peptide calculator →

Monitoring & questions

Reported side effects

IV: nausea, chest pressure, abdominal cramping, flushing, anxiety during rapid infusion (rate-dependent — slowing the infusion typically resolves)
SubQ: injection-site stinging, redness; some users describe more discomfort than typical peptide injections
Oral NR / NMN: generally well tolerated; mild GI upset, headache
Flushing (from niacin metabolites)
Theoretical: long-term effects of sustained high cellular NAD+ on sirtuin activity, cancer biology, and immune signaling are not fully characterized in humans

Reference

How it works

Acts as an electron carrier in core metabolic pathways (glycolysis, TCA cycle, oxidative phosphorylation), and as a cosubstrate for sirtuins (SIRT1–7), PARPs, and CD38. Cellular NAD+ pools decline with age and in metabolic stress; the question of whether boosting them therapeutically reverses age-related dysfunction is the crux of the field. Notably, NAD+ itself is a large polar molecule with poor membrane permeability — most of the supplementation effect is thought to come via precursor uptake (NMN, NR, niacin) followed by intracellular synthesis, not direct NAD+ entry into cells.

EvidenceTier 3 — Animal / in vitro

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Age-related cellular / metabolic decline

Tier 3high confidence

Strong preclinical and mechanistic story. Small human RCTs of oral NR and NMN show measurable increases in blood NAD+ levels but inconsistent or null effects on functional endpoints (insulin sensitivity, walking distance, cardiovascular markers). The link from 'blood NAD+ went up' to 'aging slowed' is not established in humans.

Martens CR et al. 2018 Yoshino M et al. 2021

Energy / fatigue / 'hangover recovery' (IV clinic use)

Tier 4high confidence

Marketed widely as an IV 'energy boost.' No published RCT supports this indication. Subjective reports are heavily confounded by saline volume, B-vitamin co-infusions, and clinic placebo effect.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Cognitive performance

Tier 3medium confidence

Mechanistic plausibility from sirtuin and mitochondrial roles in neurons. A handful of small human studies of NR or NMN report mixed effects on cognitive endpoints. No replicated RCTs supporting cognitive enhancement in healthy adults.

Yoshino M et al. 2021

Athletic performance / exercise capacity

Tier 3medium confidence

A few small human RCTs of NMN in amateur runners and middle-aged men report modest improvements in aerobic capacity. Effect sizes are small; methodological quality is mixed; replication outside the original lab groups is limited.

Liao B et al. 2021

Addiction recovery / withdrawal management (IV NAD+)

Tier 4high confidence

Specialty IV-NAD+ addiction-recovery clinics market this indication aggressively. Published evidence is limited to case series and small uncontrolled observational reports. No RCT.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Citations (3)

[1]
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Martens CR, Denman BA, Mazzo MR, et al. · Nature Communications · 2018 · PMID 29467442
Human RCT showing NR raises blood NAD+; null on most functional endpoints. Anchor for Tier 3 metabolic indication.
View source
[2]
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, Yoshino J, Kayser BD, et al. · Science · 2021 · PMID 33888596
Small Phase 2 RCT showing improved muscle insulin sensitivity with NMN in prediabetic women; primary human trial cited for the metabolic indication.
View source
[3]
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M · Journal of the International Society of Sports Nutrition · 2021 · PMID 34238308
Small RCT of oral NMN and aerobic capacity; anchor for Tier 3 athletic-performance indication.
View source